206 related articles for article (PubMed ID: 17177381)
1. GlcNAcstatin: a picomolar, selective O-GlcNAcase inhibitor that modulates intracellular O-glcNAcylation levels.
Dorfmueller HC; Borodkin VS; Schimpl M; Shepherd SM; Shpiro NA; van Aalten DM
J Am Chem Soc; 2006 Dec; 128(51):16484-5. PubMed ID: 17177381
[TBL] [Abstract][Full Text] [Related]
2. GlcNAcstatins are nanomolar inhibitors of human O-GlcNAcase inducing cellular hyper-O-GlcNAcylation.
Dorfmueller HC; Borodkin VS; Schimpl M; van Aalten DM
Biochem J; 2009 May; 420(2):221-7. PubMed ID: 19275764
[TBL] [Abstract][Full Text] [Related]
3. Cell-penetrant, nanomolar O-GlcNAcase inhibitors selective against lysosomal hexosaminidases.
Dorfmueller HC; Borodkin VS; Schimpl M; Zheng X; Kime R; Read KD; van Aalten DM
Chem Biol; 2010 Nov; 17(11):1250-5. PubMed ID: 21095575
[TBL] [Abstract][Full Text] [Related]
4. Insight into a strategy for attenuating AmpC-mediated beta-lactam resistance: structural basis for selective inhibition of the glycoside hydrolase NagZ.
Balcewich MD; Stubbs KA; He Y; James TW; Davies GJ; Vocadlo DJ; Mark BL
Protein Sci; 2009 Jul; 18(7):1541-51. PubMed ID: 19499593
[TBL] [Abstract][Full Text] [Related]
5. Analysis of PUGNAc and NAG-thiazoline as transition state analogues for human O-GlcNAcase: mechanistic and structural insights into inhibitor selectivity and transition state poise.
Whitworth GE; Macauley MS; Stubbs KA; Dennis RJ; Taylor EJ; Davies GJ; Greig IR; Vocadlo DJ
J Am Chem Soc; 2007 Jan; 129(3):635-44. PubMed ID: 17227027
[TBL] [Abstract][Full Text] [Related]
6. Identification of a specific inhibitor of nOGA - a caspase-3 cleaved O-GlcNAcase variant during apoptosis.
Li J; Li Z; Li T; Lin L; Zhang Y; Guo L; Xu Y; Zhao W; Wang P
Biochemistry (Mosc); 2012 Feb; 77(2):194-200. PubMed ID: 22348480
[TBL] [Abstract][Full Text] [Related]
7. Elevation of cellular O-GlcNAcylation level by a potent and selective O-GlcNAcase inhibitor based on tetrahydroimidazopyridine scaffold.
Li T; Li Z; Li J; Wang J; Guo L; Wang PG; Zhao W
Bioorg Med Chem Lett; 2012 Nov; 22(22):6854-7. PubMed ID: 23058883
[TBL] [Abstract][Full Text] [Related]
8. A divergent synthesis of 2-acyl derivatives of PUGNAc yields selective inhibitors of O-GlcNAcase.
Stubbs KA; Zhang N; Vocadlo DJ
Org Biomol Chem; 2006 Mar; 4(5):839-45. PubMed ID: 16493467
[TBL] [Abstract][Full Text] [Related]
9. Distinctive inhibition of O-GlcNAcase isoforms by an alpha-GlcNAc thiolsulfonate.
Kim EJ; Amorelli B; Abdo M; Thomas CJ; Love DC; Knapp S; Hanover JA
J Am Chem Soc; 2007 Dec; 129(48):14854-5. PubMed ID: 17994748
[TBL] [Abstract][Full Text] [Related]
10. A selective inhibitor Gal-PUGNAc of human lysosomal beta-hexosaminidases modulates levels of the ganglioside GM2 in neuroblastoma cells.
Stubbs KA; Macauley MS; Vocadlo DJ
Angew Chem Int Ed Engl; 2009; 48(7):1300-3. PubMed ID: 19130519
[TBL] [Abstract][Full Text] [Related]
11. Dissecting PUGNAc-mediated inhibition of the pro-survival action of insulin.
Teo CF; El-Karim EG; Wells L
Glycobiology; 2016 Nov; 26(11):1198-1208. PubMed ID: 27072814
[TBL] [Abstract][Full Text] [Related]
12. Screening-based discovery of drug-like O-GlcNAcase inhibitor scaffolds.
Dorfmueller HC; van Aalten DM
FEBS Lett; 2010 Feb; 584(4):694-700. PubMed ID: 20026047
[TBL] [Abstract][Full Text] [Related]
13. Tautomeric modification of GlcNAc-thiazoline.
Knapp S; Abdo M; Ajayi K; Huhn RA; Emge TJ; Kim EJ; Hanover JA
Org Lett; 2007 Jun; 9(12):2321-4. PubMed ID: 17508759
[TBL] [Abstract][Full Text] [Related]
14. Novel glucopyranoside C2-derived 1,2,3-triazoles displaying selective inhibition of O-GlcNAcase (OGA).
Igual MO; Nunes PSG; da Costa RM; Mantoani SP; Tostes RC; Carvalho I
Carbohydr Res; 2019 Jan; 471():43-55. PubMed ID: 30412832
[TBL] [Abstract][Full Text] [Related]
15. O-GlcNAcase uses substrate-assisted catalysis: kinetic analysis and development of highly selective mechanism-inspired inhibitors.
Macauley MS; Whitworth GE; Debowski AW; Chin D; Vocadlo DJ
J Biol Chem; 2005 Jul; 280(27):25313-22. PubMed ID: 15795231
[TBL] [Abstract][Full Text] [Related]
16. Chemical tools to probe cellular O-GlcNAc signalling.
Ostrowski A; van Aalten DM
Biochem J; 2013 Nov; 456(1):1-12. PubMed ID: 24156473
[TBL] [Abstract][Full Text] [Related]
17. A quantum mechanics/molecular mechanics study of the protein-ligand interaction of two potent inhibitors of human O-GlcNAcase: PUGNAc and NAG-thiazoline.
Lameira J; Alves CN; Moliner V; Martí S; Kanaan N; Tuñón I
J Phys Chem B; 2008 Nov; 112(45):14260-6. PubMed ID: 18939790
[TBL] [Abstract][Full Text] [Related]
18. Enzyme molecular mechanism as a starting point to design new inhibitors: a theoretical study of O-GlcNAcase.
Lameira J; Alves CN; Tuñón I; Martí S; Moliner V
J Phys Chem B; 2011 May; 115(20):6764-75. PubMed ID: 21542586
[TBL] [Abstract][Full Text] [Related]
19. Enzymatic characterization and inhibition of the nuclear variant of human O-GlcNAcase.
Macauley MS; Vocadlo DJ
Carbohydr Res; 2009 Jun; 344(9):1079-84. PubMed ID: 19423084
[TBL] [Abstract][Full Text] [Related]
20. O-GlcNAcase: promiscuous hexosaminidase or key regulator of O-GlcNAc signaling?
Alonso J; Schimpl M; van Aalten DM
J Biol Chem; 2014 Dec; 289(50):34433-9. PubMed ID: 25336650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
